Hansa Biopharma (HNSA.ST) Stock Price

Hansa Biopharma Price

OMX·CLOSED
46.84
​
Market closed

Over the last 17 years Hansa Biopharma grew revenue by 57.0% annually, reaching 222.27 M SEK. For Hansa Biopharma, the net margin of -240.3% is up versus -1,618.4% a few years ago. The consensus 12-month price target for Hansa Biopharma is 85.68 SEK, about 82.9% above where the stock trades today. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.

Hansa Biopharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hansa Biopharma business model & stock analysis

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases.

Frequently asked questions about Hansa Biopharma

The business model of Hansa Biopharma AB focuses on the development and commercialization of innovative immunomodulatory treatments for rare autoimmune conditions and transplant rejection. The company utilizes its proprietary technology platform, IdeS, which is designed to remove immunogenicity from biologic drugs, enhancing their safety and efficacy. With a commitment to addressing significant unmet medical needs, Hansa Biopharma leverages strategic collaborations and partnerships to advance its pipeline and bring life-changing therapies to patients. By combining scientific expertise with a patient-centric approach, the company aims to improve the lives of individuals with severe and debilitating diseases.

Hansa Biopharma AB is primarily active in the biopharmaceutical industry.

Hansa Biopharma AB faces competition from several companies in the market. Some of its main competitors include Bristol-Myers Squibb, Johnson & Johnson, and Novartis. These companies operate in the biopharmaceutical industry and offer similar products and services as Hansa Biopharma AB. By providing innovative therapies and solutions, Hansa Biopharma AB aims to gain a competitive edge in the market and expand its market share.

Hansa Biopharma AB, a leading biopharmaceutical company, has a rich history and background. Founded in 2001 and headquartered in Lund, Sweden, Hansa Biopharma specializes in developing innovative immunomodulatory treatments for patients with rare autoimmune diseases and transplant rejection. The company's mission is to improve the lives of patients by addressing unmet medical needs. With a strong focus on research and development, Hansa Biopharma has successfully brought forward novel therapies such as imlifidase, a unique enzyme used in kidney transplantation. Through its dedication to scientific excellence and commitment to patients, Hansa Biopharma has established itself as a trusted player in the biopharmaceutical industry.

Some significant milestones achieved by Hansa Biopharma AB include the FDA approval of its lead drug candidate, IdeS, for the treatment of kidney transplantation, the initiation of Phase 2 clinical trials for a potential treatment of anti-GBM antibody disease, successful completion of an IPO to strengthen financial resources, and establishment of strategic partnerships with top biotechnology companies. Hansa Biopharma AB continues to advance its innovative therapies and expand its pipeline, focusing on developing targeted immunomodulatory treatments for rare autoimmune conditions and transplant rejection.

Hansa Biopharma AB is primarily present in several countries and regions. The company operates in Europe, including Scandinavia, where it is headquartered in Sweden. Additionally, their presence extends to the United States, where they have established operations to cater to the American market. Hansa Biopharma AB's global reach indicates their commitment to expanding and serving diverse markets.

Hansa Biopharma AB represents a set of core values and a corporate philosophy focused on innovation, patient-centricity, and scientific excellence. As a leading biopharmaceutical company, Hansa Biopharma prioritizes the development of novel immunomodulatory enzyme therapies to improve the lives of patients with rare immunological conditions and transplants. The company's commitment to delivering innovative solutions and addressing unmet medical needs characterizes its corporate philosophy. Hansa Biopharma is dedicated to advancing scientific knowledge and forging strategic collaborations to drive drug discovery and development in the field of immunology.

Analysts currently set an average price target of 78.54 SEK for the Hansa Biopharma stock (median: 85.68 SEK), implying +67.7 % versus the latest price. The consensus is based on 14 analyst ratings.

14 analysts currently rate the Hansa Biopharma stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Hansa Biopharma to generate revenue of 362.20 M SEK and earnings per share of -0.33 SEK.

Converted at the current exchange rate, the Hansa Biopharma share trades at 4.22 EUR (46.84 SEK).

The Hansa Biopharma share (HNSA.ST) is listed on 6 stock exchanges, including: London (0RC7.L), Frankfurt (24H.F), München (24H.MU), Stockholm (HNSA.ST).

Hansa Biopharma AB is a Swedish biotechnology company specializing in the research and development of therapies for rare immune diseases. Founded in 2004, the company focuses on developing therapeutics for the treatment of autoimmune diseases, where the body's immune system mistakenly attacks healthy cells. Hansa Biopharma's business model is based on the discovery, development, and commercialization of therapies for rare diseases. The company specializes in the development of highly specialized technologies and platforms for antibody modification. These technologies allow the company to develop novel therapeutics for specific indications. Hansa Biopharma's products include two main products. The first is Idefirix, a medication for the treatment of acute antibody-mediated rejection of kidney transplants in patients with high immune reactivity. Idefirix has been approved by the European Commission and is currently marketed in Europe. The second product is IdeS, a proteolytic enzyme developed for the removal of antibodies from the blood of patients with high immune reactivity. IdeS is still in clinical development. Hansa Biopharma has also entered into partnerships with other pharmaceutical companies to utilize its technologies and platforms for the development of therapeutics for other indications. Some of these partnerships include: - CSL Behring: Collaboration for the development of novel antibodies for the treatment of hemophilia - Sarepta Therapeutics: Development of novel antibodies for the treatment of Duchenne muscular dystrophy - AXIS Clinicals Limited: Marketing of Idefirix in India and other Asian countries Overall, Hansa Biopharma's business model is based on the combination of research and development of new therapeutics for specific indications and collaboration with other pharmaceutical companies to leverage its technologies for the development of new therapeutics for other diseases. As the company continues to invest in the clinical development of its products, Hansa Biopharma is expected to focus on expanding its product line and expanding its reach into new geographical regions. The company will also continue to utilize its capabilities in the development of technologies and platforms for antibody modification to maximize its competitive advantage in this growing area of pharmaceutical research.

The expected revenue of Hansa Biopharma is 362.20 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Hansa Biopharma is -33.13 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Hansa Biopharma is currently -143.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hansa Biopharma stock.

The price-to-sales ratio (P/S) of Hansa Biopharma is currently 13.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hansa Biopharma stock.

The Eulerpool Quality Score for Hansa Biopharma is 7/10.

The ISIN of Hansa Biopharma is SE0002148817. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Hansa Biopharma is A0M65T. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Hansa Biopharma is HNSA.ST. The ticker symbol is used to trade Hansa Biopharma shares on the stock exchange.

Fair ValueTerminal
49.18 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
2.85 M SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Oct 17, 2007
ISIN
SE0002148817
Cusip
W4307Q109
Sedol
B2827W2
Market capitalization
3.80 B SEKMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-143.88
P/Ee 2027
-10.43
P/Ee 2028
-23.77
P/Ee 2029
2.50
P/Ee 2030
1.50
P/Se
13.16
EV/EBIT
—
P/B Ratio
6.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-63.22 %
Last updated Nov 16, 2026, 4:02 PM

Hansa Biopharma Ticker

FRANKFURT · 24H.FLONDON · 0RC7.LMUNICH · 24H.MUOTC · HNSBFSTOCKHOLM · HNSA.STSTOCKHOLM · HNSA.ST

Hansa Biopharma FIGI

HNSA:SS · BBG000QCYH36HMEDSEK:EO · BBG0058M8C51HMEDSEK:XH · BBG0058M8C88HMEDSEK:XF · BBG0058M8CB4HMEDSEK:XE · BBG0058M8CD2HMEDSEK:XJ · BBG0058M8CF0HMEDSEK:XL · BBG0058M8CG9HMEDSEK:XG · BBG0058M8CH8HMEDSEK:XO · BBG0058M8CJ6HMEDSEK:XS · BBG0058M8CN1HMEDSEK:XA · BBG0058M8CP9HMEDSEK:E1 · BBG0058M8CQ8